NCLT sanctions amalgamation of Dhanuka Laboratories with Orchid Pharma

Nclt Scheme FiledListed Co AcquisitionStrategic Transactions View source PDF Explain this filing

ORCHPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.2%Reaction day

₹850.00

prior close

₹840.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-2.0%-0.2% vs market

Pharmaceuticals peers, median of 163sector-1.1%-1.0% vs sector

On the reaction day the stock moved 0.2 pts less than Nifty Microcap 250 and 1.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.6

10m

+2.1

15m

+3.1

30m

+3.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.2-2.0-0.2-1.1-1.0

Next day

+1.3-0.1+1.4+0.2+1.1

+0.0-1.6+1.6-0.6+0.6

-1.4-2.7+1.3-0.9-0.5

+8.4+0.3+8.1+0.3+8.1

+13.9+2.0+11.8+0.6+13.2

+21.9+3.7+18.2+0.7+21.2

15d

+14.1+5.2+8.9+4.5+9.6

+18.0+3.3+14.7+3.8+14.2

+27.6+9.0+18.6+4.7+23.0

+13.9+11.8+2.1+8.4+5.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

NCLT Chennai has sanctioned the Scheme of Amalgamation of Dhanuka Laboratories Limited with Orchid Pharma Limited on June 05, 2026. By this order, Dhanuka Laboratories (Amalgamating Company) will stand transferred to and vested in Orchid Pharma (Amalgamated Company) on a going concern basis. The copy of the order will be submitted once made available by NCLT.

Likely market impact

NCLT approval clears the merger path. Dhanuka Laboratories now merges into Orchid Pharma, expanding its business base going forward.